Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical features and outcomes of first-line EGFR-TKI treatment in younger and older patients with EGFR-mutated NSCLC.

Future oncology (London, England) - 1 Jul 2025

Lai Yi-Chun, Chang Cheng-Yu, Wei Yu-Feng, Chen Chung-Yu, Chang Shih-Chieh

Abstract excerpt

BACKGROUND: The clinical characteristics and outcomes of younger versus older patients with EGFR-mutated advanced NSCLC undergoing first-line EGFR-TKI treatment remain underexplored. METHODS: This multicenter, retrospective study analyzed patients treated between 2010 and 2019. Univariate and multivariate analyses identified factors associated with outcomes. RESULTS: Among 235 patients, 38 were under 50 years and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Afatinib
Share to Age Factors
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Erlotinib Hydrochloride

Share to Lung Neoplasms

Share to Progression-Free Survival

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 40483636
DOI: 10.1080/14796694.2025.2514422
PMCID: PMC12239823

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical features and outcomes of first-line EGFR-TKI treatment in younger and older patients with EGFR-mutated NSCLC.PMID 40483636Read ↗

Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly.Semantic proximity Read ↗

Older patients with EGFR mutation-positive non-small cell lung cancer treated with afatinib in clinical practice: A subset analysis of the non-interventional GIDEON study.Semantic proximity Read ↗

Efficacy and safety findings of the EXTRA study in older adult EGFR-mutant lung cancer patients receiving afatinib as first-line treatment.Semantic proximity Read ↗

Are TKIs favourable for the elderly with non-small-cell lung cancer?Semantic proximity Read ↗

Survival analysis for older patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer after progression of first-line gefitinib.Semantic proximity Read ↗

Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study.Semantic proximity Read ↗

Real-world study of first-line therapy with aumolertinib for elderly patients with non-small cell lung cancer harboring EGFR mutation.Semantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitors in elderly patients with non-small cell lung cancer.Semantic proximity Read ↗

Real-world study of first-line therapy with aumolertinib for elderly patients with non‑small cell lung cancer harboring EGFR mutationSemantic proximity Read ↗

Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials.Semantic proximity Read ↗

Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients.Semantic proximity Read ↗

Overall survival of super-elderly (85 years or older) advanced non-small cell lung cancer patients with active epidermal growth factor receptor mutations receiving first-line gefitinib therapy: a single-institute retrospective study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.